Abstract: Spondyloarthritis (SpA) is a common rheumatic disease, which is the main cause of low back pain, young and middleaged men have high incidence. When the clinical symptoms and signs are not typical, it is easy to misdiagnose. In recent years, the guidelines for the diagnosis and treatment of SpA have been updated many times. Based on the “treat to target” treatment strategy, imaging examination plays an increasingly prominent role in the diagnosis, treatment and followup of patients with SpA. NonSteroidal Antiinflammatory drugs (NSAIDs) still belong to the basic treatment in SpA. The application opportunity and its scope and transformation principle of biological agents in SpA are clear and definite, while adopting systemic glucocorticoid therapy for active SpA in Assessment of Spondylo  Arthritis International Society(ASAS)the European League Against Rheumatism(EULAR) have been opposed. Above all, the application principles of biological agents, NSAIDs and glucocorticoids are very clear.

Key words: spondyloarthritis, diagnosis；standardized management, guidelines and consensus opinions